SuperMEN1 pp 1-15 | Cite as

MEN1 Clinical Background

  • Peter Igaz
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 668)


Multiple endocrine neoplasia Type 1 (MEN1) is a rare hereditary tumor syndrome predisposing to tumor development in several endocrine organs. Its major manifestations include hyperparathyroidism, tumors of endocrine pancreas and pituitary. Beside these three, several other endocrine (adrenocortical, foregut carcinoid) and nonendocrine (lipoma, angiofibroma, collagenoma, ependymoma, meningioma) tumors have been described to be associated with this syndrome. Both familial and sporadic forms of the disease are known. The diagnosis of MEN1 can be established if two of the three major manifestations are found in the same patient, whereas the diagnosis of familial MEN1 requires one MEN1 patient and a first degree relative with at least one MEN1 manifestation. MEN1 is transmitted as an autosomal dominant trait with high penetrance, approaching 95–100% by the age of60. Both benign (parathyroid, anterior pituitary) and malignant (gastrinoma, glucagonoma) lesions may develop in MEN1 patients. Regular surveillance of MEN1 gene mutation carriers is necessary to reveal disease manifestations. Several diagnostic modalities can be used to screen for and to examine MEN1-related tumors. The therapy of MEN1-associated tumors requires specific approach in some cases, as multiple tumors and recurrence is frequently observed.


Pituitary Adenoma Pituitary Tumor Multiple Endocrine Neoplasia Medullary Thyroid Cancer Thymic Carcinoid 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med 1954; 16:363–371.CrossRefPubMedGoogle Scholar
  2. 2.
    Brandi ML. Multiple endocrine neoplasia type 1. Rev Endocr Metab Disorders 2000; 1:275–282.CrossRefGoogle Scholar
  3. 3.
    Thakker RV. Multiple endocrine neoplasia type 1. Endocrinol Metab Clin North Am 2000; 29:541–567.CrossRefPubMedGoogle Scholar
  4. 4.
    Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658–5671.CrossRefPubMedGoogle Scholar
  5. 5.
    Karges W, Schaaf L, Dralle H et al. Clinical and Molecular diagnosis of multiple endocrine neoplasia type 1. Langenbeck’s Arch Surg 2002; 386:547–552.CrossRefGoogle Scholar
  6. 6.
    Marx SJ, Stratakis CA. Multiple endocrine neoplasia. J Intern Med 2005; 257:2–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Lakhani VT, You YN, Wells SA. The multiple endocrine neoplasia syndromes. Annu Rev Med 2007; 58: 253–265.CrossRefPubMedGoogle Scholar
  8. 8.
    Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocirne neoplasia type 1. Science 1997; 276:404–407.CrossRefPubMedGoogle Scholar
  9. 9.
    Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nature Rev Cancer 2005; 5:367–375.CrossRefGoogle Scholar
  10. 10.
    Ellard S, Hattersley AT, Brewer CM et al. Detection of an MEN 1 gene mutation depends on clinical features and supports current referral criteria for diagnostic Molecular genetic testing. Clin Endocrinol 2005; 62:169–175.CrossRefGoogle Scholar
  11. 11.
    Bilezikian JP, Brandi ML, Rubin M et al. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Int Med 2005; 257:6–17.CrossRefGoogle Scholar
  12. 12.
    Grama D, Skogseid B, Wilander E et al. Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment. World J Surg 1992; 16:611–618.CrossRefPubMedGoogle Scholar
  13. 13.
    Doherty GM. Multiple endocrine neoplasia type 1: duodenopancreatic tumors. Surg Oncol, 2003; 12:135–143.CrossRefPubMedGoogle Scholar
  14. 14.
    Gibril F, Venzon DJ, Ojeaburu JV et al. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressiveand a nonaggressive form. J Clin Endocrinol Metab 2001; 86:5282–5293.CrossRefPubMedGoogle Scholar
  15. 15.
    Soga J, Yakuwa Y: Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 1998; 17:389–400.PubMedGoogle Scholar
  16. 16.
    Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci 2001; 321:306–320.CrossRefPubMedGoogle Scholar
  17. 17.
    Soga J, Yakuwa Y: Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 1999; 18:13–22.PubMedGoogle Scholar
  18. 18.
    Beckers A, Berea D, Socin HV et al. The treatment of sporadic versus MEN1-related pituitary adenomas. J Int Med 2003; 253: 599–605.CrossRefGoogle Scholar
  19. 19.
    Waldmann J, Bartsch DK, Kann PH et al. Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening. Langenbecks Arch Surg 2007; 392:437–443.CrossRefPubMedGoogle Scholar
  20. 20.
    Teh BT, McArdle J, Chan SP et al. Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1. Medicine (Baltimore) 1997; 76:21–29.CrossRefGoogle Scholar
  21. 21.
    Scarsbrook AF, Thakker RV, Wass JAH et al. Multiple endocrine neoplasia: spectrum of radiologic appearances and discussion of a multitechnique imaging approach. Radiographies 2006; 26:433–451.CrossRefGoogle Scholar
  22. 22.
    Marini F, Falchetti A, del Monte F et al. Multiple endocrine neoplasia type 1. Orphanet J Rare Diseases 2006; 1:38–46.CrossRefGoogle Scholar
  23. 23.
    Ashgarian B, Turner MI, Gibril F et al. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab 2004; 89:5328–5336.CrossRefGoogle Scholar
  24. 24.
    Asgharian B, Chen YJ, Patronas NJ et al. Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. Clin Cancer Res 2004; 10:869–880.CrossRefPubMedGoogle Scholar
  25. 25.
    Carty SE, Helm AK, Amico JA et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 1998; 124:1106–1113.CrossRefPubMedGoogle Scholar
  26. 26.
    Olufemi SE, Green JS, Manickam P et al. Common ancestral mutation in the MENI gene is likely responsible for the prolactinoma variant of MENI (MENI Burin) in four kindreds from Newfoundland. Hum Murat 1998; 11:264–269.CrossRefGoogle Scholar
  27. 27.
    Hao W., Skarulis MC, Simonds WF et al. Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J Clin Endocrinol Metab 2004; 80:3776–3784.CrossRefGoogle Scholar
  28. 28.
    Brandi ML, Falchetti A. Genetics of primary hyperparathyroidism. Urol Int 2004; 72 Suppl: 11–16.CrossRefPubMedGoogle Scholar
  29. 29.
    Kassem M, Kruse TA, Wong FK et al. Familial isolated hyperparathyroidism as a variant of multiple endocrine neoplasia type 1 in a large Danish pedigree. J Clin Endocrinol Metab 2000; 85:165–167.CrossRefPubMedGoogle Scholar
  30. 30.
    Miedlich S, Lohmann T, Schneyer U et al. Familial isolated primary hyperparathyroidism-a multiple endocrine neoplasia type 1 variant? Eur J Endocrinol 2001; 145:155–160.CrossRefPubMedGoogle Scholar
  31. 31.
    Pannett AA, Kennedy AM, Turner JJ et al. Multiple endocrine neoplasia type 1 (MEN1) germline mutations in familial isolated primary hyperparathyroidism. Clin Endocrinol 2003; 58:639–646.CrossRefGoogle Scholar
  32. 32.
    Simonds WF, James-Newton LA, Agarwal SK et al. Familial isolated hyperparathyroidism. Clinical and genetic characteristics of 36 kindreds. Medicine 2003; 81:1–26.CrossRefGoogle Scholar
  33. 33.
    Dreijerink KMA, van Beek AP, Lentjes EGWM et al. Acromegalyin a multiple endocrine neoplasia type 1 (MEN1) family with low penetrance of the disease. Eur J Endocrinol 2005; 153:741–746.CrossRefPubMedGoogle Scholar
  34. 34.
    Daly AF, Jaffrain-Rea ML, Ciccarelli A et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 2006; 91:3316–3323.CrossRefPubMedGoogle Scholar
  35. 35.
    Burgess JR, Nord B, David R et al. Phenotype and phenocopy: the relationship between genotype and clinical phenotype in a single large family with multiple endocrine neoplasia type 1 (MEN1). Clin Endocrinol 2000; 53:205–211.CrossRefGoogle Scholar
  36. 36.
    Hai N, Aoki N, Shimatsu A et al. Clinical features of multiple endocrine neoplasia type 1 (MEN1) phenocopy without germline MEN 1 gene mutations: analysisof 20 Japanese sporadic caseswith MEN1. Clin Endocrinol 2000; 52:509–518.CrossRefGoogle Scholar
  37. 37.
    Smith JR, Oates ME. Radionuclide imaging of the parathyroid glands: patterns, pearls and pitfalls. Radiographies 2004; 24:1101–1115.CrossRefGoogle Scholar
  38. 38.
    Jensen RT. Gastrinomas, advances in diagnosis and management. Neuroendocrinology 2004; (80 Suppl. 1):23–27.CrossRefPubMedGoogle Scholar
  39. 39.
    Herder WW. Insulinoma. Neuroendocrinology 2004; (80 Suppl. 1):20–22.CrossRefPubMedGoogle Scholar
  40. 40.
    Kao PC, Taylor RL, Service FJ. Proinsulin by immunochemiluminometric assay for the diagnosis of insulinoma. J Clin Endocrinol Metab 1994; 78:1048–1051.CrossRefPubMedGoogle Scholar
  41. 41.
    Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25:458–511.CrossRefPubMedGoogle Scholar
  42. 42.
    Granberg D, Stridsberg M, Seensalu R et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1999; 84:2712–2717.CrossRefPubMedGoogle Scholar
  43. 43.
    Nobels FR, Kwekkeboom DJ, Coopmans W et al. Chromogranin A as a serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82:2622–2628.CrossRefPubMedGoogle Scholar
  44. 44.
    Perracchi M, Conte D, Gebbia C et al. Plasma chromogranin A in patients with sporadic gasrro-entcro-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur J Endocrinol 2003; 148:39–43.CrossRefGoogle Scholar
  45. 45.
    Giovanella L, La Rosa S, Ceriani L et al. Chromogranin A as serum marker of neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings. Int J Biol Markers 1999; 14:160–166.PubMedGoogle Scholar
  46. 46.
    O’Shea D, Rohrer-Theurs AW, Lynn JA et al. Localization of insulinomas by selectiveintraarterial calcium injection. J Clin Endocrinol Metab 1996; 81:1623–1627.CrossRefPubMedGoogle Scholar
  47. 47.
    Power N, Reznek RH. Imaging pancreatic islet cell tumours. Imaging 2002; 14:147–159.Google Scholar
  48. 48.
    Kaltsas G, Korbonits M, Heintz E et al. Comparison of somatostatin analog and metaiodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86:895–902.CrossRefPubMedGoogle Scholar
  49. 49.
    Kaltsas G, Rockall A, Papadogias D et al. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumors. Eur J Endocrinol 2004; 151:15–27.CrossRefPubMedGoogle Scholar
  50. 50.
    Evanson EJ. Imaging the pituitary gland. Imaging 2002; 14:93–102.Google Scholar
  51. 51.
    Lenders JWM, Eisenhofer G, Mannelli M et al. Phaeochromocytoma. Lancet 2005; 66:665–675.CrossRefGoogle Scholar
  52. 52.
    Geerdink EAM, van der Luijt RB, Lips CJM. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? Eur J Endocrinol 2003; 149:577–582.CrossRefPubMedGoogle Scholar
  53. 53.
    Balogh K, Patócs A, Majnik J et al. Genetic screening methods for the detection of mutations responsible for multiple endocrine neoplasia type 1. Mol Genet Metab 2004; 83:74–81.CrossRefPubMedGoogle Scholar
  54. 54.
    Carling T, Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med 2004; 257:1–11.Google Scholar
  55. 55.
    Carling T. Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol 2004; 17:7–12.CrossRefGoogle Scholar
  56. 56.
    Gibril F, Chen YK, Schrump DS et al. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2003; 88:1066–1081.CrossRefPubMedGoogle Scholar
  57. 57.
    Peacock M, Bilezikian JP, Klassen PS et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:135–141.CrossRefPubMedGoogle Scholar
  58. 58.
    Öberg K. Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology, 2004; (80 Suppl. 1):57–61.CrossRefPubMedGoogle Scholar
  59. 59.
    Waldherr C, Pless M, Maecke HR et al. The clinical value of (90Y-DOTA)-D-Phel-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12:941–945.CrossRefPubMedGoogle Scholar
  60. 60.
    Kwekkeboom DJ, Teunissen JJ, Bakker WH et al. Radiolabeled somatostain analog (177-Lu-DOT-AoTyr3)octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23:2754–2762.CrossRefPubMedGoogle Scholar
  61. 61.
    McCutcheon IE. Management of individual tumor syndromes: pituitary neoplasia. Endocrinol Metab Clin North Am 1994; 23:37–51.PubMedGoogle Scholar
  62. 62.
    Igaz P, Wiener Z, Szabó P et al. Functional genomics approaches for the study of sporadic adrenal tumour pathogenesis. Clinical implications. J Steroid Biochem Mol Biol 2006; 101:87–96.CrossRefPubMedGoogle Scholar
  63. 63.
    Kulke MH, Mayer RJ. Carcinoid tumors. N Eng J Med 1999; 340:858–868.CrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  • Peter Igaz
    • 1
  1. 1.2nd Department of Medicine, Faculty of MedicineSemmelweis UniversityBudapestHungary

Personalised recommendations